KRAS G13X

Variant type

missense mutation

Location

Chromosome 12

Exon

2

Protein change

p.G13X

cDNA change

-

Genomic coordinate

Chromosome 12

FATHMM prediction

-

Variant category

I

Variant description

The G13 mutations occur within the P-loop region of the G domain (Exon 2; Ensembl; 17579200) of KRAS, including p.G13A, p.G13C, p.G13D, p.G13R, p.G13S, p.G13V,and et al.. Multiple studies have now shown that patients with tumors harboring mutations in KRAS or NRAS exons 2, 3, or 4 are unlikely to benefit from anti-EGFR antibody therapy given in combination with chemotherapy (PMID: 24812410; 24024839; 23597769; 24356622; 24756373; 24512508). Moreover, KRAS mutations are negative predictors of radiographic response to the EGFR tyrosine kinase inhibitors [for review, see (PMID: 18832458; 19349489)]. Currently, there are no direct anti-KRAS therapies available.

Variant frequence

This section displays the distribution of mutated samples and tissue types (top 5).

Accoiciated drug